Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape
Open Access
- 1 January 2012
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 3, 21
Abstract
Despite the impressive progress over the past decade, in the field of tumor immunology, such as the identification of tumor antigens and antigenic peptides, there are still many obstacles in eliciting an effective immune response to eradicate cancer. It has become increasingly clear that tumor microenvironment plays a crucial role in the control of immune protection. Tumors have evolved to utilize hypoxic stress to their own advantage by activating key biochemical and cellular pathways that are important in progression, survival, and metastasis. Hypoxia-inducible factor (HIF-1) and vascular endothelial growth factor (VEGF) play a determinant role in promoting tumor cell growth and survival. Hypoxia contributes to immune suppression by activating HIF-1 and VEGF pathways. Accumulating evidence suggests a link between hypoxia and tumor tolerance to immune surveillance through the recruitment of regulatory cells (regulatory T cells and myeloid derived suppressor cells). In this regard, hypoxia (HIF-1α and VEGF) is emerging as an attractive target for cancer therapy. How the microenvironmental hypoxia poses both obstacles and opportunities for new therapeutic immune interventions will be discussed.Keywords
This publication has 100 references indexed in Scilit:
- VHL and HIF signalling in renal cell carcinogenesisThe Journal of Pathology, 2010
- Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem CellsCancer Cell, 2009
- COX-2 expression and function in the hyperalgesic response to paw inflammation in miceProstaglandins, Leukotrienes and Essential Fatty Acids, 2008
- HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and InvasionCancer Cell, 2008
- Biology of hypoxia-inducible factor-2α in development and diseaseCell Death & Differentiation, 2008
- Hypoxia and cancerJournal of Molecular Medicine, 2007
- Hypoxia-Inducible Factors, Stem Cells, and CancerCell, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapiesThe Journal of Pathology, 2002
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996